Trial reportJournal of cancer research and clinical oncology2006
Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma.
Trial report in Journal of cancer research and clinical oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Cardioprotective interventions for cancer patients receiving anthracyclines.The Cochrane database of systematic reviews · 2011Pooled it
- Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.BMC cancer · 2010Pooled it
- Succinylation of 14-3-3 theta by CPT1A promotes survival and paclitaxel resistance in nasal type extranodal natural killer/T-cell lymphoma.Translational oncology · 2024Article
- The Role of the Natural Antioxidant Mechanism in Sperm Cells.Reproductive sciences (Thousand Oaks, Calif.) · 2022Review
- Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity.Biomedicines · 2022Review
- Understanding Anthracycline Cardiotoxicity From Mitochondrial Aspect.Frontiers in pharmacology · 2022Review
- Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets.Heart failure reviews · 2021Review
- African Vegetables (Oxidative medicine and cellular longevity · 2020Article
- L-Carnitine supplementation reduces the general fatigue of cancer patients during chemotherapy.Molecular and clinical oncology · 2018Article
- Protecting the heart in cancer therapy.F1000Research · 2018Review
- Micronutrients in Oncological Intervention.Nutrients · 2016Review
- Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.American journal of translational research · 2016Review
- Integrative Therapies and Cardiovascular Disease in the Breast Cancer Population: A Review, Part 1.Integrative medicine (Encinitas, Calif.) · 2015Review
- Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Paediatric drugs · 2014Review
- The role of antioxidants in the era of cardio‑oncology.Cancer chemotherapy and pharmacology · 2013Review
- Chemotherapy-induced cardiotoxicity.Current heart failure reports · 2012Review
- Role of carnitine in cancer chemotherapy-induced multiple organ toxicity.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2010Article
- Carnitine deficiency and oxidative stress provoke cardiotoxicity in an ifosfamide-induced Fanconi Syndrome rat model.Oxidative medicine and cellular longevityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChemotherapy regimens based on anthracycline (doxorubicin) are well established in lymphoma therapy. The purpose of this study was to examine the effects of L-carnitine with a view to reducing cytotoxic side-effects.
methods20 patients were scheduled to receive 3 g L-carnitine before each chemotherapy cycle, followed by 1 g L-carnitine/day during the following 21 days, while 20 patients received a placebo (randomized controlled trial). The plasma lipid profile and relative mRNA levels of key enzymes of oxidative metabolism (carnitine acyltransferases) were measured at three points of time. In addition to the clinical parameters we used the mRNA of white blood cells to evaluate the toxic effects on cardiomyocytes.
resultsIn the present study no cardiotoxicity of anthracycline therapy was detected. Carnitine treated patients showed a rise in plasma carnitine which led to an increase of relative mRNA levels from CPT1A (liver isoform of carnitine palmitoyltransferase) and OCTN2 (carnitine transporter). Following chemotherapy, an activation of carnitine acyltransferases was associated with a stimulation of OCTN2 in both groups.
conclusionBiochemical and molecular analyses indicated a stimulation of oxidative metabolism in white blood cells through carnitine uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.